Neovacs Ord Share Price (0W8U)

lupus (lupus erythematosus or disseminated lupus erythematosus)

?

Lupus is an autoimmune, chronic and debilitating disease, the etiology of which has not yet been well researched. The disease is progressive, characterized by an alternation of relapses and phases of remissions. Lupus can affect many organs and tissues (skin, kidneys, joints, heart, lungs, nervous system, etc.) and manifests itself as heterogeneous clinical symptoms (rashes, arthritis, sensitivity to light, kidney damage, neurological disorders, anemia, etc.). The disease mainly affects women (9 women for 1 man). The prevalence is estimated at 1 in 1,000 to 1 in 3,000.

?

There is no cure for lupus. The only treatments available aim to reduce inflammation and associated pain in order to manage the main symptoms of the disease and avoid complications. Currently, the basic treatment is based on the use of the synthetic anti-malarial drug hydroxychloroquine, whose anti-inflammatory properties have a therapeutic and preventive effect on relapses and enable long-term disease control. Treatment of relapses must then be tailored to the severity and the organs affected and is usually based on the use of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressants alone or in combination.

Interferon alpha (IFNa) is a cytokine whose role in the pathophysiology in lupus. has been clearly confirmed

We are currently developing a kinoid vaccine against IFNa. Our clinical studies of phases I / IIa and IIb showed the neutralization of this cytokine, a biological and clinical effect in lupus, according to disease-specific criteria (see publication).

there is no specific treatment for allergies. Asthma symptoms can be relieved by inhaling bronchodilators to reduce the feeling of tightness when breathing. In the case of food allergies, the avoidance of the allergen must be strictly implemented. It is also possible to create a desensitization protocol, but it will remain long and sensitive once the allergen is identified.

Interleukin-4 (IL-4), interleukin-13 (IL-13) and immunoglobulin E (IgE) play a key role in allergic reactions.

We are currently developing a Kinoid vaccine that targets IL-4 and IL-13 at the same time. The neutralization of these two cytokines in a mouse mite allergy model showed a therapeutic effect on respiratory capacity and bronchial mucosal cells in mice.

In connection with food allergies, we are also developing the kinoid vaccine against IL-4 and IL-13, as well as a kinoid vaccine against IgE.

https://www.tipranks.com/stocks/nvcn/forecast

https://www.reddit.com/r/wallstreetbetsGER/comments/nyxg0g/******_report_neovacs/?utm_medium=android_app&utm_source=share

allergy manifests itself as an excessive and inappropriate immune reaction after encountering an antigen of a foreign substance. It begins with a sensitization phase in which a previously harmless antigen is recognized as an allergen. This first phase prepares the immunological basis for a more or less strong reaction on the next contact with the allergen.

In recent years, the number of allergy sufferers has increased dramatically, especially in industrialized countries with a predominance of respiratory and food allergies.

Allergic asthma

?

Allergic asthma is characterized by a chronic inflammatory reaction of the bronchi, which leads to difficulty breathing. It can be caused, for example, by mites or various pollen.

Food allergies

?

In the case of a food allergy, the immune system recognizes a food antigen as well as a bacterium or a microbe as a harmful foreign substance. The manifestations can be respiratory, cutaneous, or intestinal and the most severe form is anaphylaxis.

There is no specific treatment for allergies. Asthma symptoms can be relieved by inhaling bronchodilators to reduce the feeling of tightness when breathing. In the case of food allergies, the avoidance of the allergen must be strictly implemented. It is also possible to create a desensitization protocol, but it will remain long and sensitive once the allergen is identified.

Interleukin-4 (IL-4), interleukin-13 (IL-13) and immunoglobulin E (IgE) play a key role in allergic reactions.

We are currently developing a Kinoid vaccine that targets IL-4 and IL-13 at the same time. The neutralization of these two cytokines in a mouse mite allergy model showed a therapeutic effect on respiratory capacity and bronchial mucosal cells in mice.

In connection with food allergies, we are also developing the kinoid vaccine against IL-4 and IL-13, as well as a kinoid vaccine against IgE.

We are currently developing a Kinoid vaccine that targets IL-4 and IL-13 at the same time. The neutralization of these two cytokines in a mouse mite allergy model showed a therapeutic effect on respiratory capacity and bronchial mucosal cells in mice.

In connection with food allergies, we are also developing the kinoid vaccine against IL-4 and IL-13, as well as a kinoid vaccine against IgE.